Similar to EGFR, while ALK inhibitors are effective in initially treating tumors harboring the EML4-ALK mutation, secondary ALK mutations and EMT desensitize patients to ALK targeted treatment [175], and the acquired resistance to next generation ALK inhibitors in NSCLC is most common in hypoxia via induction of EMT [175]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.